PT-141 Is Vyleesi: The Approved U.S. Formulation and Why It Matters

PT-141 is not a vague wellness label in the U.S. In approved form, it is bremelanotide injection sold as Vyleesi, and that name swap changes how you judge every claim that follows.

What PT-141 actually is in the U.S.

The cleanest way to think about it is simple: PT-141 is the nickname, while Vyleesi is the FDA-approved prescription product. The label says it is bremelanotide, 1.75 mg per 0.3 mL, in a single-dose disposable prefilled autoinjector for subcutaneous use.

That matters because the route is part of the product, not a footnote. The approval date was June 21, 2019, and the indication was narrow on purpose: acquired, generalized hypoactive sexual desire disorder in premenopausal women.

The label also says it is not indicated for postmenopausal women or for men. That is not marketing fine print. It is the boundary of the evidence the FDA actually reviewed.

Why the label matters for results and access

Once you know the approved form, the buying questions get clearer fast. If you're seeing PT-141 discussed as a nasal spray, that is a different delivery idea than the U.S.

product on the label. The evidence behind Vyleesi does not automatically transfer to a different route, because route changes how a drug is absorbed, how predictable the dose feels, and what kind of claim is even fair to make. The public price trail is also more concrete than most wellness chatter. The manufacturer’s site says the cash price can be about $1,199 for a single carton, while a pharmacy marketplace page has shown Vyleesi around three figures to low four figures depending on supply and checkout path. The brand also advertises help-to-pay support, which is a reminder that the real decision is not just what the label says, but what you may actually pay at the counter.

If you want the most grounded read, start with the approved product, then ask three plain questions: is this the injection on the label, is the dosing route the same, and does the price line up with the prescription product rather than a looser PT-141 claim? That sequence keeps you anchored to the evidence and helps you separate a real regulated medicine from an eye-catching shorthand. How to read PT-141 claims without getting lost: The two phase 3 trials behind approval were randomized and identical, and they tested the approved injectable form in the labeled population. That is the evidence base you want in mind when a sales page sounds broad, fast, or universal.

It does not mean the medicine has no interest. It means the strongest data sits with a specific drug, a specific route, and a specific group. That is the practical win here. Once you translate PT-141 into Vyleesi, you can read the label with less guesswork, compare prices without mixing formats, and decide whether a claim is actually talking about the approved product or something else wearing the same name. If you want the next layer deeper, the most useful follow-up is how the approved dose feels in practice, where the side effects usually show up, and why some PT-141 marketing keeps drifting away from the product the FDA approved.